• By clicking "OK" or continuing to use this site, you agree that we may collect and use your personal data and set cookies to improve your experience and customise advertising. To see how, and to learn how to control cookies, please read our Privacy Policy and Cookie Policy.
OK
Advertisement

We only need a few more clicks to be able to show the most read stories for this topic. Take a look at the latest headlines below and help us out by clicking on what you find interesting!

In the last 2 hours
In the last 4 hours
In the last 6 hours
AJMC® in the Press, December 6, 2024 American Journal of Managed Care15:04
In the last 8 hours
Earlier today
Yesterday
How Tirzepatide Benefits Patients With Obesity-Related HFpEF American Journal of Managed Care17:52 5-Dec-24
Tirzepatide Outperforms Semaglutide in Weight Loss Trial American Journal of Managed Care15:49 5-Dec-24
Tirzepatide approved by NICE The Diabetes Times11:51 5-Dec-24
What is Mounjaro and how does it work? Evening Standard11:46 5-Dec-24
In the last 7 days
In the last month
view more headlines
6 Dec 18:39

About our Tirzepatide news

Latest news on Tirzepatide, a drug that is being developed as a potential treatment for obesity and type 2 diabetes. It is a synthetic hormone that is designed to mimic the effects of natural hormones called incretins, which help to lower blood sugar and reduce appetite. Tirzepatide has shown promise in clinical trials, producing significant weight loss in people with obesity or type 2 diabetes. It is administered as a once-weekly injection, and it is believed to work by increasing the production of a hormone called GLP-1, which helps to regulate appetite and insulin production. Tirzepatide is currently in late-stage clinical trials, and it is expected to be considered for regulatory approval in the coming years.


Publication filters

Headline Density

Sorry, no headlines or news topics were found. Please try different keywords.